Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Glioblastoma is the most malignant brain tumour with high mortality.
Cancer stem cells are thought to be crucial for tumour initiation and its recurrence after standard therapy with radiation and temozolomide (TMZ) chemotherapy.
Protein tyrosine phosphatase receptor type Z (PTPRZ) is an enzyme that is highly expressed in glioblastoma, especially in cancer stem cells.
The research group of Professor Masaharu Noda and Researcher Akihiro Fujikawa of the National Institute for Basic Biology (NIBB) showed that the enzymatic activity of PTPRZ is requisite for the maintenance of stem cell properties and tumourigenicity in glioblastoma cells.
PTPRZ knockdown strongly inhibited tumour growth of C6 glioblastoma cells in a mouse xenograft model.
In addition, the research team discovered NAZ2329, an allosteric inhibitor of PTPRZ, in collaboration with ASUBIO Pharma Co. Ltd..
NAZ2329 efficiently suppressed stem cell-like properties of glioblastoma cells in culture, and tumour growth in C6 glioblastoma xenografts.
These results indicate that pharmacological inhibition of PTPRZ is a promising strategy for the treatment of malignant gliomas.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.